Psychotic Disorders Clinical Trial
Official title:
Protocol for a Multi-study Programme of Research on Untreated Psychosis in India, Nigeria, and Trinidad
INTREPID II aims to investigate variability in incidence, presentation, outcome, and impact
of untreated psychotic disorders in three countries - India, Nigeria, and Trinidad - through
four interconnected observational studies:
1. Study 1 on Incidence, Presentation, and Risk has the objective to investigate the
incidence and presentation of untreated psychotic disorders in each setting and
associated risk factors.
2. Study 2 on Course and Outcome has the objective to investigate two-year course and
outcome of psychotic disorders and associated factors.
3. Study 3 on Help-seeking and Impact has the objective to investigate (a) help-seeking;
and (b) the impact of psychotic disorders on individuals and families, using a
combination of quantitative and qualitative approaches.
4. Study 4 on Physical Health has the objective to investigate the types and prevalence of
physical health problems and related biological markers.
INTREPID II comprises four interconnected studies. As a basis for these studies, the
researchers are identifying, assessing, and following, in each catchment area,
population-based cohorts of cases (individuals with an untreated psychotic disorder) and
controls (individuals with no history of a psychotic disorder). In each setting, the
researchers will identify, assess, and follow at 2 years cohorts of 240 cases with a
psychotic disorder (total, 720) and 240 matched controls (total, 720), using methods and
infrastructure developed during a feasibility and pilot study, INTREPID I. The inclusion and
exclusion criteria for cases are in line with those used in previous studies, including the
World Health Organization (WHO) multi-country studies, and are purposefully broad to capture
heterogeneity and to allow sub-analyses by duration of untreated psychosis.
The study sample includes cases, controls and relatives or caregivers:
Sample (1) Cases
To estimate incidence, the researchers aim to identify all individuals with an untreated
psychotic disorder (cases) within each catchment area. Untreated is defined as never having
received treatment with anti-psychotic medication for one continuous month prior to the start
of the case-finding period.
In each catchment area, the researchers are using a multi-pronged approach to case
identification. First, using procedures developed in INTREPID I, the researchers have
established comprehensive case detection systems by mapping and seeking to engage a
comprehensive set of service providers and community key informants who may encounter
individuals with psychotic disorders within the catchment area. This includes the
professional sector (specialist and generalist services; public, private and third sector),
the folk sector (including traditional and religious services), and the popular sector (i.e.
informal sources of support). Second, the researchers give providers and informants materials
developed in the INTREPID I pilot work that detail, using local terms and language, the
experiences and behaviours that characterise psychosis. Third, in each catchment area,
researchers check with each provider and informant regularly and conduct regular checks of
admissions ledgers and registers for in-patient and out-patient services (where these exist),
to identify potential cases. In addition, in rural villages in Chennai and Ibadan, field
workers visit village meeting points to enquire about potential cases. Potential cases are
then screened for inclusion using the Screening Schedule for Psychosis, an instrument that
has been widely used in epidemiological studies of psychoses. Those who screen positive and
who meet inclusion criteria are approached and informed consent sought.
Case-finding began on 1 May 2018 and will conclude 30 April 2020. At the end of the
case-finding period, the researchers will conduct leakage studies in each setting to identify
possible cases meeting the study's inclusion criteria who may not have been identified. Each
research team will systematically re-check admissions ledgers and registers for in-patient
and out-patient services and complete final checks with healers and key informants.
All eligible cases identified through the incidence study are invited to participate in the
programme. Rates of refusal are documented and basic data (i.e. age, gender, area of
residence, sector of identification, and where possible ethnicity, religion, duration of
untreated psychosis and mode of onset) is collected for those who decline to participate, or
who it is not possible to interview, to assess non-response bias.
Sample (2) Controls
Age-, sex- and neighbourhood-matched controls are recruited to provide indicative population
data against which to compare cases in terms of hypothesised risk factors, social outcomes,
and physical health. The researchers use the Psychosis Screening Questionnaire to collect
information on any current or past experiences of psychosis. In the absence of a readily
accessible sampling frame to randomly select potential controls, the researchers map the ten
nearest neighbouring households for each case, listing all residents in these dwellings by
sex and age. All potential controls for the case (defined as the same gender and ±5 years of
age) are then approached in random order, until an eligible control is identified. When no
match is identified the process is repeated. This approach was successfully piloted in all
settings.
Sample (3) Relatives and Caregivers
The researchers seek consent from each case to approach a close relative or caregiver to
participate in the study. They then approach each designated relative to seek his/her
consent. The primary purposes of including relatives are to corroborate and extend
information from cases (e.g., physical health and illness), to collect information on
premorbid adjustment, family history of mental disorder, and other risk factors, and to
collect information on family responses to psychosis, help-seeking, and impact (burden) on
family.
Follow-up
All participants will be followed at 2 years. To facilitate this, the researchers collect
detailed contact information at baseline (address, telephone number, email address if
applicable, service provider details) from each case and control, including details of a
relative or friend who can be contacted to trace the individual. In addition, to maintain
contact and minimise attrition, the researchers contact participants every six months, by
telephone or in person, to confirm or update contact details. Based on the INTREPID I pilot
work, the researchers expect to re-assess around 80% of cases and controls 2 years after
initial identification.
Sample size
In each setting, the researchers anticipate (based on pilot findings) identifying around 300
untreated cases. Of those, given an expected refusal rate of 20% of all eligible cases (based
on the INTREPID I pilot work), the researchers anticipate recruiting approximately 240 cases
with a psychotic disorder (total, 720), and 240 individually matched controls (total, 720).
These sample sizes are larger than most previous studies and provide good statistical power
to test the study hypotheses (i.e., > 80% at p 0.05). For example: (1) with samples of around
300 incident cases in each setting, the researchers will have over 80% power to detect an
incidence rate ratio of 1.5 (or greater) between two areas (e.g., urban vs. rural), if the
incidence rate in the lowest risk area is 20 per 100,000; (2) with a sample of 240 cases and
240 controls in each setting, the researchers will have over 80% power to detect an odds
ratio of 2.0 (or greater) in case-control comparisons when the prevalence of exposure (risk
factor) is at least 15% in controls; (3) using gender as an example, with a sample of 192
cases followed at 2 years in each setting, the researchers will have 80% power (or greater)
to detect a difference in the proportion of cases with a poor outcome (e.g., continuously
psychotic) of 0.20 (20%) or greater, when the proportion of men with a poor outcome is 0.40
and the proportion of women is 0.20 (i.e., equivalent to an odds ratio of ~ 2.5).
Data collection
To test the hypotheses and address the research questions of INTREPID II's four studies, the
researchers collect information from cases, relatives, and controls at baseline and at 2 year
follow up. All measures, where necessary, have been translated into local languages and back
translated to check equivalence.
All those who consent are interviewed and assessed by trained research workers using
structured instruments and protocols either at home or at a local clinic. For participants
who are in contact with health services, interview data are supplemented with reference to
clinical notes, with participants' consent.
Interviews and assessments are conducted by researchers fluent in the local language. To
ensure consistency of methods across settings, all researchers are fully trained using a
mixture of online materials and exercises, with feedback, and face to face training,
delivered both by the United Kingdom (UK) team and locally by senior researchers under the
supervision of the country principal investigators (PIs). All PIs are experienced
psychiatrists with extensive backgrounds in both national and international research.
Inter-rater reliability for core instruments that require rater judgement will be tested
regularly across settings using video-recorded interviews with cases and controls to ensure
that the measures are applied consistently throughout the duration of the programme.
Responses will be triangulated with relative reports and, where applicable, clinical records.
Reliability
All measures will be applied identically, by the same research team, for both cases and
controls (where measures apply to both groups). Researchers from across the field settings
rated video-taped interviews at study onset and their ratings were compared to gold standard
responses developed by the PIs.
Analysis Plan
The researchers will use standard summary statistics, with indicators of spread and precision
as appropriate (e.g., crude incidence rates per 100,000 person years, with 95% confidence
intervals) to describe the data. They will then use appropriate regression models to compare
data between and within settings (e.g., Poisson regression for incidence rates and other
count data; Cox regression for time-to-event data; logistic regression (including
multinomial) for categorical data [e.g., course type]; and linear regression for continuous
data [e.g., GAF score, blood pressure]). In building regression models, the researchers will
first fit univariable models, then test for effect modification by core variables (e.g.,
gender, age, setting, and time), and finally adjust for putative confounders of each
hypothesised association by fitting multivariable models.
Where appropriate, the researchers will use multiple imputation to deal with missing data. In
addition, or where assumptions necessary for imputation are not met, researchers will (re)
conduct analyses on participants with complete data only. Where possible, analyses based on
imputed data will be presented, with complete data analyses presented as sensitivity analyses
in supplementary materials.
Framework Analysis will be used to analyse qualitative data, adopting an iterative process of
reading and annotating transcripts to identify salient themes, which will form the basis for
comparisons between and within settings.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05321602 -
Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder
|
Phase 1 | |
Terminated |
NCT03230097 -
This Study Tests Whether BI 409306 Prevents Patients With a Specific Type of Mental Illness (Attenuated Psychosis Syndrome) From Becoming Worse. This Study Looks at How Well Patients Tolerate the Medicine and How Effective it is Over 1 Year
|
Phase 2 | |
Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
Active, not recruiting |
NCT05726617 -
Avatar Intervention for the Treatment of Cannabis Use Disorder in Patients With Severe Mental Health Disorders
|
N/A | |
Not yet recruiting |
NCT03807388 -
ReMindCare App for Patients From First Episode of Psychosis Unit.
|
N/A | |
Recruiting |
NCT02874573 -
Tocilizumab in Schizophrenia
|
Phase 1 | |
Terminated |
NCT02584114 -
Brain Effects of Memory Training in Early Psychosis
|
N/A | |
Completed |
NCT02906553 -
The Role of Nitric Oxide in Cognition in Schizophrenia
|
N/A | |
Terminated |
NCT02841956 -
Reducing Duration of Untreated Psychosis Through Rapid Identification and Engagement
|
N/A | |
Withdrawn |
NCT02213887 -
Study of the Effects of Pantoprazole on Levels of Prescribed Psychiatric Medications
|
Phase 4 | |
Completed |
NCT01981356 -
Acceptance and Commitment Therapy for the Inpatient Treatment of Psychosis
|
Phase 0 | |
Recruiting |
NCT02848469 -
Irish Omega-3 Study
|
Phase 2 | |
Recruiting |
NCT02009969 -
Serial Comparisons of Abdominal and Neurological MRI Scans
|
N/A | |
Completed |
NCT02648321 -
Motivational Intervention for Physical Activity in Psychosis
|
N/A | |
Enrolling by invitation |
NCT00762866 -
Psychiatric Genotype/Phenotype Project Repository
|
||
Completed |
NCT00484302 -
Specialized Addiction Treatment Versus Treatment as Usual for Young Patients With Cannabis Abuse and Psychosis
|
N/A | |
Completed |
NCT00455234 -
Rapid Tranquillization Trial: TREC-India II
|
Phase 3 | |
Completed |
NCT00130923 -
Risperidone Long-acting Versus Oral Risperidone in Patients With Schizophrenia and Alcohol Use Disorder
|
Phase 4 | |
Completed |
NCT00844922 -
Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)
|
Phase 2 | |
Completed |
NCT00130676 -
A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression
|
Phase 3 |